Literature DB >> 9100997

Absolute bioavailability of bromfenac in humans.

K Gumbhir-Shah1, W H Cevallos, S A DeCleene, C E Halstenson, J M Korth-Bradley.   

Abstract

OBJECTIVE: To estimate absolute bioavailability of bromfenac and to compare its pharmacokinetics after intravenous and oral administration.
DESIGN: This was a randomized, open-label, single-dose, crossover study conducted under fasting conditions with a washout period of at least 48 hours between doses. Each subject received a 50-mg dose of bromfenac both intravenously and orally followed by collection of blood samples at specified time intervals. Bromfenac plasma concentrations were measured by using a validated HPLC method with ultraviolet detection.
SETTING: The study was conducted at the Drug Evaluation Unit. Hennepin County Medical Center, Minneapolis, MN.
SUBJECTS: The participants consisted of 12 healthy subjects between 18 and 45 years of age and within +/-15% of ideal body weight.
RESULTS: The mean +/- SD absolute bioavailability of bromfenac was 67% +/- 20%.
CONCLUSIONS: The pharmacokinetic parameters of bromfenac were similar after intravenous and oral administration, suggesting that the prototype oral dosage form is optimal and that the observed intersubject variability is due to bromfenac itself, not the type of dosage form.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9100997     DOI: 10.1177/106002809703100401

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  4 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of bromfenac.

Authors:  N M Skjodt; N M Davies
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Synergistic Cytotoxicity from Drugs and Cytokines In Vitro as an Approach to Classify Drugs According to Their Potential to Cause Idiosyncratic Hepatotoxicity: A Proof-of-Concept Study.

Authors:  Ashley R Maiuri; Bronlyn Wassink; Jonathan D Turkus; Anna B Breier; Theresa Lansdell; Gurpreet Kaur; Sarah L Hession; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2017-07-07       Impact factor: 4.030

3.  Cytotoxic Synergy Between Cytokines and NSAIDs Associated With Idiosyncratic Hepatotoxicity Is Driven by Mitogen-Activated Protein Kinases.

Authors:  Ashley R Maiuri; Anna B Breier; Lukas F J Gora; Robert V Parkins; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2015-05-07       Impact factor: 4.849

4.  Impacts of diphenylamine NSAID halogenation on bioactivation risks.

Authors:  Mary Alexandra Schleiff; Sasin Payakachat; Benjamin Mark Schleiff; S Joshua Swamidass; Gunnar Boysen; Grover Paul Miller
Journal:  Toxicology       Date:  2021-06-06       Impact factor: 4.571

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.